Background Diabetic nephropathy is the leading cause of end-stage renal disease.
Interruption of the renin–angiotensin system slows the progression of renal disease in …

Background: Diabetic nephropathy has become the single most important cause of end-
stage renal disease (ESRD) worldwide. Strategies to slow the rate of loss of renal function in …

Aims/hypothesis The renal and cardiovascular protective effects of angiotensin receptor
blocker (ARB) remain controversial in type 2 diabetic patients treated with a contemporary …

OBJECTIVE—To evaluate the within-trial effect of losartan and conventional
antihypertensive therapy (CT) compared with placebo and CT on the economic cost …

Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic
proportions. Individuals with diabetes are not only more likely to develop hypertension …

Background Diabetic nephropathy is the leading cause of end-stage renal disease in
developed countries. We evaluated the renoprotective effects of dual blockade of the renin …

The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal
protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has …

Background It is unknown whether either the angiotensin-II–receptor blocker irbesartan or
the calcium-channel blocker amlodipine slows the progression of nephropathy in patients …

OBJECTIVE—Metabolic factors such as glycemic control, hyperlipidemia, and hyperkalemia
are important considerations in the treatment of patients with type 2 diabetes and …

Renin angiotensin system inhibitor therapy is seldom offered to individuals who have
diabetes and advanced chronic kidney disease because of safety concerns. In this post hoc …